Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

Core Insights - Absci has appointed Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of its Scientific Advisory Board, effective January 1, 2024, to enhance its AI-enabled drug discovery efforts [1][2] - Sir Pangalos brings over 25 years of experience in drug discovery and development, having previously served as Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, where he significantly improved R&D productivity [1][2] - Absci's innovative 'zero-shot' generative AI model is positioned to reshape drug discovery, with recent collaborations including an AI-designed antibody for oncology and a partnership with Almirall for dermatological therapeutics [2] Company Overview - Absci is a generative AI drug creation company that integrates AI with scalable wet lab technologies to accelerate drug development and improve therapeutic outcomes [3] - The company's Integrated Drug Creation™ platform allows for the screening of billions of cells weekly, enabling rapid progression from AI-designed antibodies to wet lab-validated candidates in as little as six weeks [3] - Absci's headquarters is located in Vancouver, WA, with additional facilities in New York City and Zug, Switzerland [3]